Research abstract:

Few studies have examined therapist effects and therapeutic alliance (TA) in treatments for chronic fatigue syndrome (CFS). Therapist effects are the differences in outcomes achieved by different therapists. TA is the quality of the bond and level of agreement regarding the goals and tasks of therapy.

Prior research suffers the methodological problem that the allocation of therapist was not randomized, meaning therapist effects may be confounded with selection effects.

We used data from a randomized controlled treatment trial of 296 people with CFS. The trial compared pragmatic rehabilitation (PR), a nurse led, home based self-help treatment, a counselling-based treatment called supportive listening (SL), with general practitioner  treatment as usual. Therapist allocation was randomized.

Primary outcome measures, fatigue and physical functioning were assessed blind to treatment allocation. TA was measured in the PR and SL arms. Regression models allowing for interactions were used to examine relationships between (i) therapist and therapeutic alliance, and (ii) therapist and average treatment effect (the difference in mean outcomes between different treatment conditions).

We found no therapist effects. We found no relationship between TA and the average treatment effect of a therapist. One therapist formed stronger alliances when delivering PR compared to when delivering SL (effect size 0.76, SE 0.33, 95% CI 0.11 to 1.41). In these
therapies for CFS, TA does not influence symptomatic outcome. The lack of significant  therapist effects on outcome may result from the trial’s rigorous quality control, or random therapist allocation, eliminating selection effects. Further research is needed.

Therapist effects and the impact of early therapeutic alliance on symptomatic outcome in Chronic Fatigue Syndrome, by Lucy P. Goldsmith Graham Dunn Richard P. Bentall, Shon W. Lewis, Alison J. Wearden in PlosOne Vol. 10, no.12, December 14, 2015

This entry was posted in News and tagged , . Bookmark the permalink.

Comments are closed.